Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma.

ABSTRACT: Multimodality therapy including surgical resection is the current paradigm in treating malignant pleural mesothelioma (MPM), a thoracic surface cancer without cure. The main limitation of all surgical approaches is the lack of long-term durability because macroscopic complete resection (R1 resection) commonly predisposes to locoregional relapse. Over the years, there have been many studies that describe various intrapleural strategies that aim to extend the effect of surgical resection. The majority of these approaches are intraoperative adjuvants. Broadly, there are three therapeutic classes that employ diverse agents. The most common, widely used group of adjuvants are comprised of direct therapeutics such as intracavitary chemotherapy (± hyperthermia). By comparison, the least commonly

SUBMITTER: Choi AY 

PROVIDER: S-EPMC9108281 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature